These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 38601497)

  • 41. Carbapenem-Resistant Gram Negative Bacilli Are Predominantly Multidrug or Pan-Drug Resistant.
    Kannian P; Mahanathi P; Ashwini V; Vaishnavi M; Priya C
    Microb Drug Resist; 2021 Aug; 27(8):1057-1062. PubMed ID: 33417816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review.
    Palacios-Baena ZR; Giannella M; Manissero D; Rodríguez-Baño J; Viale P; Lopes S; Wilson K; McCool R; Longshaw C
    Clin Microbiol Infect; 2021 Feb; 27(2):228-235. PubMed ID: 33130270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
    J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
    de la Fuente C; Rodríguez M; Merino N; Carmona P; Machuca I; Córdoba-Fernández M; Guzmán-Puche J; Domínguez A; López-Viñau T; García L; Vaquero JM; Robles JC; Martínez-Martínez L; Torre-Cisneros J
    Int J Antimicrob Agents; 2023 Jul; 62(1):106818. PubMed ID: 37062445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
    Righi E; Mutters NT; Guirao X; Del Toro MD; Eckmann C; Friedrich AW; Giannella M; Kluytmans J; Presterl E; Christaki E; Cross ELA; Visentin A; Sganga G; Tsioutis C; Tacconelli E
    Clin Microbiol Infect; 2023 Apr; 29(4):463-479. PubMed ID: 36566836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of TMexCD-TOprJ-producing carbapenem-resistant Gram-negative bacteria from hospital sewage.
    Zhu J; Lv J; Zhu Z; Wang T; Xie X; Zhang H; Chen L; Du H
    Drug Resist Updat; 2023 Sep; 70():100989. PubMed ID: 37480594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting acquisition of carbapenem-resistant Gram-negative pathogens in intensive care units.
    Dantas LF; Dalmas B; Andrade RM; Hamacher S; Bozza FA
    J Hosp Infect; 2019 Oct; 103(2):121-127. PubMed ID: 31039381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Gram-negative bacteria of critical priority in ICU patients from a tertiary care hospital].
    Uc-Cachón AH; Molina-Salinas GM; Dzul-Beh AJ; Rosado-Manzano RF; Dzib-Baak HE
    Rev Med Inst Mex Seguro Soc; 2023 Sep; 61(5):552-558. PubMed ID: 37756682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended-Spectrum Beta-Lactamase and Carbapenem-Resistant Gram-Negative Pathogens in Makkah, Saudi Arabia.
    Kabrah A
    Ethiop J Health Sci; 2022 Nov; 32(6):1221-1230. PubMed ID: 36475249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
    Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study.
    de Souza GHA; de Oliveira AR; Dos Santos Barbosa M; Rossato L; da Silva Barbosa K; Simionatto S
    J Infect Public Health; 2023 Aug; 16(8):1184-1192. PubMed ID: 37271099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence of catheter-associated urinary tract infections by Gram-negative bacilli and their ESBL and carbapenemase production in specialized hospitals of Bahir Dar, northwest Ethiopia.
    Asmare Z; Awoke T; Genet C; Admas A; Melese A; Mulu W
    Antimicrob Resist Infect Control; 2024 Jan; 13(1):10. PubMed ID: 38273339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations.
    Carrara E; Savoldi A; Piddock LJV; Franceschi F; Ellis S; Sharland M; Brink AJ; Harris PNA; Levy-Hara G; Rohit A; Tsioutis C; Zayyad H; Giske C; Chiamenti M; Bragantini D; Righi E; Gorska A; Tacconelli E
    Clin Microbiol Infect; 2022 Jan; 28(1):66-72. PubMed ID: 33975010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The occurrence of Salmonella, extended-spectrum β-lactamase producing Escherichia coli and carbapenem resistant non-fermenting Gram-negative bacteria in a backyard poultry flock environment.
    Shah DH; Board MM; Crespo R; Guard J; Paul NC; Faux C
    Zoonoses Public Health; 2020 Sep; 67(6):742-753. PubMed ID: 32710700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units.
    Zhou JJ; Patel SJ; Jia H; Weisenberg SA; Furuya EY; Kubin CJ; Alba L; Rhee K; Saiman L
    Infect Control Hosp Epidemiol; 2013 Mar; 34(3):274-83. PubMed ID: 23388362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it's even arrived?
    Russo C; Mesini A; Mariani M; Tavella E; Sette C; Ugolotti E; Bartalucci C; Palmero C; Bandettini R; Castagnola E
    J Infect Public Health; 2024 Apr; 17(4):624-631. PubMed ID: 38422857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and validation of nomograms for predicting the risk probability of carbapenem resistance and 28-day all-cause mortality in gram-negative bacteremia among patients with hematological diseases.
    Jian X; Du S; Zhou X; Xu Z; Wang K; Dong X; Hu J; Wang H
    Front Cell Infect Microbiol; 2022; 12():969117. PubMed ID: 36683699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S; Kritsotakis EI; Gikas A
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The problem of multi-resistance in gram-negative bacilli in intensive care units: Treatment and prevention strategies.
    Garnacho-Montero J; Amaya-Villar R
    Med Intensiva (Engl Ed); 2022 Jun; 46(6):326-335. PubMed ID: 35545496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.
    ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C
    Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.